GlaxoSmithKline told a Delaware federal judge on Monday that it will seek enhanced damages on a $235 million verdict against Teva Pharmaceutical for willfully infringing a patent for its hypertension drug Coreg.
The announcement came in a joint letter from the parties detailing plans for the litigation in the wake of a June 20 federal jury awarding a total of $235.4 million to GlaxoSmithKline—$234.1 million for lost profits and an added $1.4 million in royalties—after a six-day trial in Wilmington.
